New Zealand medicines with clinical-trial evidence for a new indication
34 of the 461 medicines with a NZTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (9 at L1, 25 at L2), meaning clinical-trial evidence (randomised trials, Phase 2–3 trials or systematic reviews) was found for it.
The medicines come from the Pharmac Community Pharmaceutical Schedule (a funding schedule, not a licence register: Medsafe licence status is not included); the list reflects the drug reports as last updated on 2026-11-20.
Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.
Medicines with trial evidence (L1–L2)
| Drug | Predicted new indication | Evidence level | Registered trials cited (NCT) |
|---|---|---|---|
| Acetylcysteine | thrombotic disease | L1 | 7 |
| Bendamustine | mantle cell lymphoma | L1 | 10 |
| Bupropion | attention deficit-hyperactivity disorder | L1 | 6 |
| Busulfan | myelodysplastic syndrome | L1 | 10 |
| Clomipramine | Anxiety disorder | L1 | 8 |
| Dapsone | Pneumocystosis | L1 | 10 |
| Doxorubicin | Ewing sarcoma | L1 | 11 |
| Ketamine | Headache disorder | L1 (with caveat) | 9 |
| Tacrolimus | Seborrheic dermatitis | L1 | 3 |
| Atorvastatin | HIV infectious disease | L2 | 10 |
| Citalopram | obsessive-compulsive disorder | L2 | 4 |
| Clozapine | Manic bipolar affective disorder | L2 | 1 |
| Diazepam | Insomnia (disease) | L2 | 0 |
| Everolimus | Liposarcoma | L2 | 3 |
| Goserelin | Amenorrhea (disease) | L2 | 1 |
| Hydrocortisone | Alopecia areata | L2 | 1 |
| Hydrocortisone Acetate | Alopecia areata | L2 | 1 |
| Ledipasvir | Hepatitis B virus infection | L2 | 5 |
| Lenalidomide | Myeloid leukemia | L2 (with caveat) | 11 |
| Levonorgestrel | Acne (disease) | L2 | 0 |
| Mefenamic Acid | Headache disorder | L2 (with caveat) | 0 |
| Moclobemide | Agoraphobia | L2 | 0 |
| Montelukast | Bronchitis | L2 | 10 |
| Mycophenolate Mofetil | HIV infectious disease | L2 (with caveat) | 4 |
| Nortriptyline | Attention deficit-hyperactivity disorder | L2 | 0 |
| Oxaliplatin | Malignant pleural mesothelioma | L2 (with caveat) | 3 |
| Pazopanib | Liposarcoma | L2 (with caveat) | 8 |
| Pimecrolimus | Seborrheic dermatitis | L2 | 2 |
| Prednisolone | Alopecia areata | L2 | 0 |
| Sucralfate | Duodenogastric reflux | L2 | 0 |
| Sunitinib | Liposarcoma | L2 | 2 |
| Tocilizumab | Ankylosing spondylitis | L2 | 4 |
| Ustekinumab | Dermatitis | L2 | 6 |
| Vinorelbine | Ewing sarcoma | L2 | 3 |
How to read this list
- Evidence level follows the site's criteria: L1 = Multiple Phase 3 RCTs / systematic reviews; L2 = Single RCT or multiple Phase 2 trials. "(with caveat)" means the drug report qualifies the grade; read the note in the report before relying on it.
- Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, but some predictions may still overlap an established use; the report explains this where it applies.
- Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
- For all levels and the full method, see High Evidence (L1-L2), All Drugs and the methodology.
Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)